Adaptyx Biosciences, a Menlo Park-based biowearables company, has raised $14 million in seed financing to advance its groundbreaking platform for continuous, multi-analyte molecular monitoring. The round was led by Interlagos, with significant participation from Overwater Ventures, and joined by Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub, Hyperlink Ventures, Cantos Ventures, Humba Ventures, and Seaside Ventures, bringing the company's total funding to $23 million since inception.
Revolutionary Technology Platform
Adaptyx's biowearable platform represents a significant advancement in continuous health monitoring, extending far beyond glucose to capture a comprehensive range of human biochemistry including small molecules, electrolytes, hormones, drugs, and proteins. The technology addresses what CEO and Co-Founder Vijit Sabnis, Ph.D., describes as healthcare's fundamental "data deficit."
"Lab tests are only snapshots of health and don't capture the body's changing physiology, leaving blind spots that prevent addressing many of today's health challenges," Sabnis explained. "Adaptyx gives patients and clinicians a continuous view of what's happening inside the body, transforming previously unseen molecular signals into empowering insights."
At the core of the platform are programmable molecular switches—laboratory-made DNA bioreceptors designed to bind target molecules with high sensitivity and specificity. Upon analyte recognition, these switches undergo predictable and reversible structural changes, enabling continuous, precise tracking of diverse biomarkers and establishing a new class of modular biosensors.
Accelerated Development Through AI
The company's Molecular Switch Foundry integrates automated molecular design, parallelized screening, and AI-driven optimization to compress development timelines from years to weeks. According to Chief Science Officer and Co-Founder Alex Yoshikawa, Ph.D., "Each new switch generates structured datasets that make the system smarter and faster, rapidly expanding the analyte library and powering new applications."
This approach allows Adaptyx to aim for adding hundreds of biomolecules to its continuous monitoring capabilities, establishing what the company describes as a foundational molecular data platform needed for personalized medicine.
Clinical Applications in Development
Adaptyx has identified several key applications for its technology:
Heart Failure Management: Continuous monitoring of electrolytes, kidney function markers, and cardiac biomarkers enables safe medication titration, early detection of abnormalities, and prompt intervention before decompensation occurs.
Hormone Optimization: Continuous hormone and metabolite profiling reveals rhythms and imbalances, supporting precise management of endocrine health, from metabolic disorders to fertility care.
Care Delivery Augmentation: Real-time monitoring of drug levels and critical care biomarkers ensures optimal dosing, rapid clinical response, and reduced risk of complications.
Personalized Wellness: Continuous tracking of molecular health markers provides visibility into stress, metabolism, and recovery, enabling proactive lifestyle adjustments and healthier aging.
Strong Scientific Foundation
The technology builds on more than a decade of innovation at Stanford University and the Chan Zuckerberg Biohub by Professors H. Tom Soh and Joseph M. DeSimone. Professor Soh, who serves as Co-Founder and Scientific Advisor, noted, "After 17 years developing this technology in academia, we're ready to bring continuous molecular monitoring from the lab to real patients. The ability to continuously track multiple biomarkers simultaneously is a breakthrough that will transform how we understand human health and improve care for everyone."
Adaptyx, founded in 2022, holds an exclusive license to the intellectual property from this research, establishing a strong foundation for its technology and future growth.
Investment and Future Plans
The new funding will accelerate R&D and product development, expand the molecular switch pipeline, and support ongoing clinical trials towards the company's first application. Adaptyx will also scale its team across engineering, data science, and clinical operations.
"Adaptyx's technical expertise in the science of molecular sensing is the bedrock of the business," said Achal Upadhyaya, Founder and CEO of Interlagos Capital and Adaptyx board member. "Engineering a novel device to sense biological datasets fundamentally transforms the way we will measure and deliver healthcare."
Kristina Simmons, Founder and General Partner at Overwater Ventures, emphasized the transformative potential: "Adaptyx is exactly the kind of category-defining innovation healthcare has been waiting for. This team isn't chasing incremental change—they're re-architecting how we observe physiology, continuously and at scale."
The company is pursuing FDA clearance for clinical applications initially, with plans to expand into broader health and wellness markets. Adaptyx's continuous monitoring technology is currently investigational and not yet available for sale.
